http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106619662-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1682 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate | 2016-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106619662-B |
| titleOfInvention | Oral dry suspension containing tenofovir disoproxil fumarate and preparation method thereof |
| abstract | The invention discloses an oral dry suspension containing tenofovir disoproxil fumarate and a preparation method thereof, wherein the oral dry suspension is prepared from the following components in parts by mass: 40 parts of raw materials, 200-800 parts of carriers and 40-300 parts of pharmaceutically acceptable auxiliary materials; wherein the raw material is tenofovir disoproxil fumarate or a composition of tenofovir disoproxil fumarate and emtricitabine; the carrier is one or more of polyethylene glycol, glyceryl monostearate, polyacrylic resin and ethyl cellulose; the pharmaceutically acceptable adjuvants include suspending agent, lubricant and correctant. The oral dry suspension containing tenofovir disoproxil fumarate is stable in property, suitable for patients to take, good in dissolution rate, simple in production process and suitable for industrial scale operation. |
| priorityDate | 2016-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 106.